Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.

Guy M Goodwin,Scott T Aaronson,Oscar Alvarez,Peter C Arden, Annie Baker,James C Bennett,Catherine Bird,Renske E Blom,Christine Brennan, Donna Brusch,Lisa Burke, Kete Campbell-Coker,Robin Carhart-Harris, Joseph Cattell, Aster Daniel,Charles DeBattista,Boadie W Dunlop,Katherine Eisen,David Feifel, MacKenzie Forbes, Hannah M Haumann,David J Hellerstein, Astrid I Hoppe,Muhammad I Husain,Luke A Jelen,Jeanine Kamphuis, Julie Kawasaki,John R Kelly, Richard E Key,Ronit Kishon,Stephanie Knatz Peck,Gemma Knight,Martijn H B Koolen,Melanie Lean,Rasmus W Licht,Jessica L Maples-Keller, Jan Mars,Lindsey Marwood,Martin C McElhiney, Tammy L Miller, Arvin Mirow,Sunil Mistry,Tanja Mletzko-Crowe, Liam N Modlin,René E Nielsen,Elizabeth M Nielson, Sjoerd R Offerhaus,Veronica O'Keane,Tomáš Páleníček,David Printz, Marleen C Rademaker, Aumer van Reemst,Frederick Reinholdt,Dimitris Repantis,James Rucker,Samuel Rudow,Simon Ruffell,A John Rush,Robert A Schoevers,Mathieu Seynaeve, Samantha Shao,Jair C Soares,Metten Somers, Susan C Stansfield, Diane Sterling, Aaron Strockis,Joyce Tsai, Lucy Visser,Mourad Wahba, Samuel Williams,Allan H Young, Paula Ywema,Sidney Zisook,Ekaterina Malievskaia

The New England journal of medicine（2022）

引用 162|浏览23

暂无评分

摘要

In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.).

查看译文

关键词

major depression,single-dose single-dose,treatment-resistant

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要